TY - JOUR AB - Patient‑derived tumor xenograft (PDTX) models are established by transferring patient tumors into immunodeficient mice. In these murine models, the characteristics of the primary tumor are retained, including the microenvironment of tumor cell growth and histopathology. Due to this, it has become the most reliable in vivo human cancer model. However, the success rates differ by type of tumor, site of transplantation and tumor aggressiveness. Subcutaneous transplantation is a standard method for PDTX, and subrenal capsule transplantation improves the engraftment rate. Recently, PDTX models are frequently used in the fields of precision medicine, predictive biomarkers, evaluation of drug efficacy and preclinical research on tumor immunotherapeutic drugs. The aim of the present article was to review the establishment, clinical applications and limitations of the PDTX model in tumor research. AD - The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China Department of Oncology, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China AU - Yin,Zhenyu AU - Maswikiti,Ewetse,Paul AU - Liu,Qian AU - Bai,Yuping AU - Li,Xiaomei AU - Qi,Wenbo AU - Liu,Le AU - Ma,Yanling AU - Chen,Hao DA - 2021/11/01 DO - 10.3892/etm.2021.10640 IS - 5 JO - Exp Ther Med KW - tumors xenograft patient‑derived tumor xenograft precision medicine PY - 2021 SN - 1792-0981 1792-1015 SP - 1206 ST - Current research developments of patient‑derived tumour xenograft models (Review) T2 - Experimental and Therapeutic Medicine TI - Current research developments of patient‑derived tumour xenograft models (Review) UR - https://doi.org/10.3892/etm.2021.10640 VL - 22 ER -